Shattuck Labs is developing first-in-class monoclonal antibodies targeting the DR3 receptor for inflammatory diseases, notably SL-325 for inflammatory bowel disease (IBD). The company’s proprietary approach aims to offer superior pathway blockade and immunogenicity profile compared to existing TL1A blockers. Financially, Shattuck Labs shows steady reduction in losses driven by clinical progress, supported by a solid cash runway extending into 2029. Phase 1 trials of SL-325 are underway with Phase 2 initiation planned in Crohn’s Disease patients by Q3 2026. Key risks include regulatory uncertainties, capital needs, and competitive pressures typical of early-stage biotech.